Literature DB >> 28837274

Association Between Bone Mineral Density and Depressive Symptoms in a Population-Based Sample.

Rocco D Hlis1, Roger S McIntyre2, Naim M Maalouf3, Erin Van Enkevort1, E Sherwood Brown4,1.   

Abstract

OBJECTIVE: This analysis was conducted to determine the relationship between bone mineral density (BMD) and depressive symptoms in a population-based cohort.
METHODS: Data were extracted from the second phase of the Dallas Heart Study (DHS-2), a large, multiethnic population sample in Dallas County, Texas, from September 1, 2007, to December 31, 2009. Depressive symptom severity was measured with the 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR₁₆), which is derived from DSM-IV major depressive disorder criteria. BMD was measured using dual-energy x-ray absorptiometry. Multiple linear regressions examined the relationship between QIDS-SR₁₆ score and BMD controlling for age, body mass index, sex, ethnicity, smoking status, alcohol use status, serum 25-hydroxyvitamin D concentration, antidepressant use, and physical activity as measured by total vigorous and moderate metabolic equivalents. Subgroup analyses explored differences related to age.
RESULTS: QIDS-SR₁₆ score was not a significant predictor of either lumbar spine or total hip T-score (β = -0.01, P = .61 and β = -0.02, P = .39) in the overall population (n = 2,285). There was a significant negative interaction term between age and QIDS-SR₁₆ group (β = -0.01, P = .01). In participants aged 60 years or older (n = 465), QIDS-SR₁₆ score was a significant predictor of BMD at the lumbar spine and total hip (β = -0.14, P = .003 and β = -0.12, P = .006, respectively).
CONCLUSIONS: QIDS-SR₁₆ score did not significantly predict BMD in the overall DHS-2 sample. There was, however, a significant association observed in participants aged ≥ 60 years. Results suggest that diagnosis and treatment of depressive symptoms may be of clinical importance in older individuals, a subgroup at high risk for osteoporosis and fractures. © Copyright 2018 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2018        PMID: 28837274     DOI: 10.4088/JCP.16m11276

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Relationship between inflammatory biomarker galectin-3 and hippocampal volume in a community study.

Authors:  Megan K Lowther; Jarrod P Tunnell; Jayme M Palka; Darlene R King; Damilola C Salako; Dimitri G Macris; Jay B Italiya; Justin L Grodin; Carol S North; E Sherwood Brown
Journal:  J Neuroimmunol       Date:  2020-09-08       Impact factor: 3.478

2.  Relationship between novel inflammatory biomarker galectin-3 and depression symptom severity in a large community-based sample.

Authors:  Darlene R King; Damilola C Salako; Samia Kate Arthur-Bentil; Arielle E Rubin; Jay B Italiya; Jenny S Tan; Dimitri G Macris; Hunter K Neely; Jayme M Palka; Justin L Grodin; Kaylee Davis-Bordovsky; Matthew Faubion; Carol S North; E Sherwood Brown
Journal:  J Affect Disord       Date:  2020-12-15       Impact factor: 4.839

3.  The effect of depression on fracture healing and osteoblast differentiation in rats.

Authors:  Chunzi Nie; Zhan Wang; Xufeng Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-29       Impact factor: 2.570

4.  Impact of age on optimal dose of antidepressants.

Authors:  Kenji Hashimoto
Journal:  EClinicalMedicine       Date:  2020-01-03

5.  Fluoxetine improves bone microarchitecture and mechanical properties in rodents undergoing chronic mild stress - an animal model of depression.

Authors:  Raymond W Lam; Hee-Kit Wong; Ramruttun A Kumarsing; Anna N Chua; Roger C Ho; Roger S McIntyre; Cyrus S Ho
Journal:  Transl Psychiatry       Date:  2022-08-20       Impact factor: 7.989

6.  Evaluation of the increased risk of spine fracture in patients with mood disorder compared with matched controls: a longitudinal follow-up study using a national sample cohort in Korea.

Authors:  So Young Kim; Chanyang Min; Bumjung Park; Miyoung Kim; Hyo Geun Choi
Journal:  BMJ Open       Date:  2019-11-28       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.